Finding could make diagnosis more precise

FROM CONSUMERAFFAIRS.COM

Researchers have determined that a molecule produced by the body’s metabolism could be used to differentiate between benign prostate tissue vs. localized and metastatic prostate cancer.

They also found that this molecule, known as sarcosine, may be associated with prostate cancer invasiveness and aggressiveness. The findings, reported by researchers at the Michigan Center for Translational Pathology, appear in the current issue of Nature.

“Current biomarkers for detection or progression of prostate cancer are not as precise as we would like. Therefore, a more accurate indicator of cancer is of great interest,” said Sudhir Srivastava, Ph.D., chief of the National Cancer Institute’s Cancer Biomarkers Research Group. “Sarcosine and some other select metabolites may be excellent indicators of cancer progression.”

Multiple complex molecular events characterize cancer development and progression. Determining which molecular networks dictate whether cancer will be confined to the prostate or spread to other parts of the body could lead to the identification of critical biomarkers associated with prostate cancer invasion and aggressiveness.

FOR COMPLETE STORY, PLEASE CLICK HERE.

~Sandy G.